$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Medical Research

FDA Approves Cosentyx for Polymyalgia Rheumatica Patients

Novartis announced on Tuesday, November 17, 2026, that the Food and Drug Administration approved Cosentyx (secukinumab) 150 mg for adults with polymyalgia rheumatica who have had an inadequate response to corticosteroids or cannot tolerate a corticosteroid taper. It is the first anti-IL-17 biologic approved for the disease and the drug's 11th United States indication.

TML Health DeskNov 17, 8:01 AM ET · 2 min read

Edited and fact-checked by Stephen Sprague

The Novartis Pavillon on the company's Basel campus (archive). Novartis announced the FDA approval from Basel on November 17, 2026. Photo: MBxd1, CC BY-SA 4.0, via Wikimedia Commons.
Summary

The approval gives rheumatologists a second road for patients who relapse on steroids or cannot taper off them. The trial number that carries it is a remission rate that doubled the placebo rate at one year.

Tap a passage. React to the part that matters.

The Food and Drug Administration has approved Cosentyx for adults with polymyalgia rheumatica who cannot stay on steroids.

Novartis announced the approval on Tuesday, November 17, 2026. The approval covers the 150 mg dose of Cosentyx, whose generic name is secukinumab, for adults whose disease responded inadequately to corticosteroids or who cannot tolerate a corticosteroid taper. Cosentyx is the first and only biologic that targets interleukin-17 approved for this disease in the United States, and polymyalgia rheumatica is the drug's 11th approved United States indication.

The evidence is a randomized trial, not a registry or a case series. The Phase III REPLENISH trial, registered as NCT05767034, ran in 27 countries as a double-blind, placebo-controlled study. Patients received Cosentyx 300 mg, Cosentyx 150 mg, or placebo, each paired with a 24-week steroid taper. At Week 52, 40.5 percent of patients on the 150 mg dose held sustained remission, against 20.5 percent on placebo. The results were published in the New England Journal of Medicine and presented at the EULAR Congress on June 3, 2026.

John Stone of Harvard Medical School and Massachusetts General Hospital led the trial as global principal investigator. He said patients with this disease face a higher risk of poor outcomes from steroids, and that the prospect of months or years of added steroid treatment is disheartening. In the trial, secukinumab doubled the likelihood of sustained remission and helped patients taper off steroids.

The disease is common in older adults. Novartis puts the United States population living with polymyalgia rheumatica at about 966,000 people. It usually starts after age 50 with acute pain and stiffness in the shoulders, neck, and hips. Relapses hit up to 40 percent of patients in the first year, and long-term steroid use raises the risk of osteoporosis, cardiovascular disease, and diabetes.

The limits sit in the safety table. Serious adverse events occurred in 15.9 percent of patients on Cosentyx 150 mg and 14.2 percent on placebo. Hypersensitivity reactions ran 14 percent against 9 percent, and urinary tract infections ran 13 percent against 7 percent. One serious urinary tract infection occurred in the 150 mg group, and one patient treated with Cosentyx died of cryptococcal meningitis. The approval covers the 150 mg dose only. The indication is already approved in the European Union, and regulators in Japan are still reviewing it.

What changes on Tuesday is the choice set. A patient who relapses on steroids or cannot finish a taper now has an approved biologic option with a decade of use in other immune diseases behind it. The remission figure is a rate at one year in one trial, and it is the number every later comparison will have to beat.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.